• Cinoxacin: Mechanism, Spectrum, and Clinical Evidence

  2026-08-27

  The reference paper presents Cinoxacin as a DNA synthesis-inhibiting quinolone antibiotic with rapid urinary exposure, activity against important Enterobacteriaceae, and a clinical role in initial and recurrent bacterial urinary tract infections. Its integrated discussion of antimicrobial susceptibility, pharmacokinetics, adverse reactions, and therapeutic outcomes remains useful for interpreting urinary tract infection research and designing comparative laboratory studies.

• Propranolol Beyond β-Blockade: A Translational Playbook

  2026-08-26

  Propranolol is more than a cardiovascular tool: its non-selective β-adrenergic receptor blockade connects receptor pharmacology with adipose metabolism, inflammatory signaling, and neurobehavioral research. This article translates recent burn-injury metabolomics into practical study-design guidance for researchers evaluating cardiovascular regulation, emotional memory modulation, hypertension treatment, and essential tremor therapy.

• Gepotidacin in Uncomplicated UTI: EAGLE-2 and EAGLE-3

  2026-08-26

  The EAGLE-2 and EAGLE-3 phase 3 trials evaluated oral gepotidacin against nitrofurantoin for uncomplicated urinary tract infection using a rigorous double-blind, double-dummy non-inferiority design. Gepotidacin was non-inferior in both studies and superior in EAGLE-3, supporting further development of a first-in-class oral antibiotic with a distinct bacterial topoisomerase mechanism.

• Gamithromycin: Mechanism, PK/PD, and Workflows

  2026-08-25

  Gamithromycin, also known as ML-1709460, is a 15-membered semi-synthetic macrolide antibiotic for respiratory-pathogen research and veterinary applications. Its principal value is target-site exposure in lung tissue and pulmonary epithelial lining fluid, interpreted with the AUC24h/MIC pharmacodynamic index.

• Azilsartan (TAK-536): From AT1 Biology to Translation

  2026-08-24

  Azilsartan (TAK-536) provides a precise way to interrogate AT1 receptor signaling across cardiovascular, renin-angiotensin system, and neuroinflammation models. This article connects mechanistic findings from reactive astrocyte–microglia research with practical study design, product handling, and translational strategy.

• Gepotidacin Pharmacokinetics in Adults and Elderly

  2026-08-24

  This phase I reference study characterizes the pharmacokinetics, safety, and tolerability of Gepotidacin, also known as GSK2140944, across single and repeat oral dosing in healthy adults and elderly participants. Its dose-proportional exposure, predictable accumulation, and limited food effect provide a translational foundation for further antibacterial development while distinguishing pharmacokinetic evidence from clinical efficacy.

• Sisomicin vs Tobramycin: In Vitro Activity

  2026-08-23

  Stewart and Bodey evaluated sisomicin against 565 clinical isolates and compared its minimum inhibitory concentrations with gentamicin, Tobramycin, amikacin, butirosin, and kanamycin. The study showed strong activity against most Gram-negative bacilli, while its cross-resistance pattern with gentamicin and Tobramycin highlighted the importance of amikacin for antibiotic resistance research.

• Geneticin, G-418 Sulfate: Assay Reliability

  2026-08-22

  A scenario-driven guide to using Geneticin, G-418 Sulfate (SKU A2513) for cell selection, viability, proliferation, cytotoxicity, and antiviral workflows. It connects mechanism, stock preparation, kill-curve design, data interpretation, and practical product-selection criteria for more defensible laboratory results.

• CAPE Inhibits TcdB and Modulates CDI

  2026-08-22

  The reference study identifies caffeic acid phenethyl ester (CAPE) as a candidate antivirulence compound that inhibits the Clostridioides difficile toxin TcdB while reshaping infection-associated gut microbiota. Its combination of phenotypic screening, toxin-mechanism assays, mouse infection experiments, microbiome profiling, and metabolite analysis provides a useful framework for developing anti-infection research strategies that do not rely solely on bacterial killing.

• Cefoperazone: From MIC Data to Biliary Models

  2026-08-21

  Cefoperazone sodium salt connects β-lactamase-resistance research with reproducible antimicrobial assays and biliary tract infection models. This article interprets historical comparative data and translates the compound’s physicochemical and pharmacokinetic properties into practical experimental decisions.

• Temafloxacin Against Gram-Positive Bacteria

  2026-08-20

  The 1991 reference study combined new broth microdilution data with a literature review to define temafloxacin’s enhanced in-vitro activity against clinically important Gram-positive cocci. Its comparisons with ciprofloxacin and ofloxacin, together with testing under altered pH, serum, urine, magnesium, and inoculum conditions, provide a useful framework for interpreting fluoroquinolone susceptibility assays.

• Temafloxacin Combinations in Mycobacterium avium Complex

  2026-08-20

  A 1993 study evaluated clarithromycin, temafloxacin, and ethambutol against pigmented and non-pigmented Mycobacterium avium complex strains using extracellular MIC/FIC testing and macrophage-based intracellular killing assays. The results showed that combination activity was strain-dependent, while the three-drug regimen produced the strongest intracellular bactericidal effect, supporting combination screening rather than reliance on single-agent MICs alone.

• Ceftazidime in Gram-Negative Infection Research

  2026-08-19

  Ceftazidime combines strong activity against aerobic Gram-negative bacteria, including Pseudomonas aeruginosa, with a practical workflow for susceptibility, infection-model, and resistance-transmission studies. This guide translates recent carbapenem-resistant Enterobacter cloacae findings into assay design, stock handling, controls, and troubleshooting decisions.

• Penicillin G Sodium: Workflow and Assay Optimization

  2026-08-19

  Build reproducible susceptibility, time-kill, and infection-model workflows with Penicillin G Sodium while accounting for penicillinase activity, solution stability, and exposure timing. The article also adapts a mechanistic assay-design lesson from oncology research without conflating 5-azacytidine findings with antibiotic biology.

• ZCL278 and the Translational Logic of Cdc42 Inhibition

  2026-08-18

  Cdc42 is emerging as a mechanistically actionable node in cell migration, neuronal development, and kidney fibrosis. This thought-leadership guide positions ZCL278 as a research tool for connecting biochemical target engagement with spatial phenotypes and fibrosis-relevant signaling, while distinguishing validated evidence from translational hypotheses.

7976 records 2/532 page Previous Next 12345 下5页 Last page